JP2023113636A5 - - Google Patents
Info
- Publication number
- JP2023113636A5 JP2023113636A5 JP2023077286A JP2023077286A JP2023113636A5 JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5 JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody polypeptide
- polypeptide
- single variable
- variable domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511245P | 2017-05-25 | 2017-05-25 | |
| US62/511,245 | 2017-05-25 | ||
| JP2019564951A JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
| PCT/US2018/034330 WO2018217988A1 (en) | 2017-05-25 | 2018-05-24 | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Division JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023113636A JP2023113636A (ja) | 2023-08-16 |
| JP2023113636A5 true JP2023113636A5 (https=) | 2025-11-28 |
Family
ID=62599725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Pending JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
| JP2023077286A Pending JP2023113636A (ja) | 2017-05-25 | 2023-05-09 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Pending JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200148779A1 (https=) |
| EP (1) | EP3630832A1 (https=) |
| JP (2) | JP2020521458A (https=) |
| KR (2) | KR102847736B1 (https=) |
| CN (1) | CN110637035A (https=) |
| WO (1) | WO2018217988A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| WO2017214452A1 (en) | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| WO2019195126A1 (en) | 2018-04-02 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CN114599389A (zh) * | 2019-08-22 | 2022-06-07 | 奇达拉治疗公司 | 变体fc结构域及其用途 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN115485302A (zh) * | 2020-03-09 | 2022-12-16 | 百时美施贵宝公司 | 具有增强的激动剂活性的针对cd40的抗体 |
| CN115443147A (zh) * | 2020-04-23 | 2022-12-06 | 伊莱利利公司 | 抗体的皮下吸收和生物利用度 |
| JP7523586B2 (ja) | 2020-05-18 | 2024-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 改善された薬物動態特性を有する抗体変異体 |
| CN112552389B (zh) * | 2020-08-07 | 2023-06-06 | 中爱瑞祥(杭州)生物科技有限公司 | 一种活性肽融合蛋白及其制备方法 |
| CA3196766A1 (en) * | 2020-11-02 | 2022-05-05 | Attralus, Inc. | Sap fc fusion proteins and methods of use |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US9051373B2 (en) * | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| EP2471813B1 (en) * | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| KR20080073293A (ko) * | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| HUE038848T2 (hu) | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| EP3113796A1 (en) * | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| BR112018006251A2 (pt) * | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
| US11220550B2 (en) * | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
-
2018
- 2018-05-24 US US16/495,994 patent/US20200148779A1/en not_active Abandoned
- 2018-05-24 EP EP18731284.8A patent/EP3630832A1/en active Pending
- 2018-05-24 WO PCT/US2018/034330 patent/WO2018217988A1/en not_active Ceased
- 2018-05-24 KR KR1020247019564A patent/KR102847736B1/ko active Active
- 2018-05-24 KR KR1020197037759A patent/KR20200012907A/ko not_active Ceased
- 2018-05-24 JP JP2019564951A patent/JP2020521458A/ja active Pending
- 2018-05-24 CN CN201880032964.0A patent/CN110637035A/zh active Pending
-
2023
- 2023-05-09 JP JP2023077286A patent/JP2023113636A/ja active Pending
-
2025
- 2025-08-28 US US19/313,261 patent/US20260042858A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023113636A5 (https=) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| US10442857B2 (en) | Anti-IL-17 antibodies | |
| ES2569217T3 (es) | Agente para tratar enfermedades | |
| JP2020184996A5 (https=) | ||
| US7179465B2 (en) | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon | |
| JP2020525032A5 (https=) | ||
| JP7745113B2 (ja) | 多重特異性抗体およびその使用 | |
| JP2022507741A5 (https=) | ||
| JP2020521458A5 (https=) | ||
| JP2020193210A5 (https=) | ||
| JP2014530611A5 (https=) | ||
| RU2008152443A (ru) | Антитела высокой аффинности к il-6-рецептору человека | |
| JP2017099391A5 (https=) | ||
| JP7680078B2 (ja) | 抗ヒトインターフェロンα受容体１モノクローナル抗体及びその使用 | |
| JP2010500005A5 (https=) | ||
| JP2014513953A5 (https=) | ||
| JP2020532285A5 (https=) | ||
| CN106102837A (zh) | 经由细胞受体锚定使用具有天然架构的双特异性抗体改良的hiv‑1‑中和抗体效力和广度 | |
| KR20240029115A (ko) | 개선된 ｔｎｆ 결합제 | |
| KR20140108520A (ko) | CD1d에 대한 항체 | |
| JP2022521956A5 (https=) | ||
| Vance et al. | Resolution of two overlapping neutralizing B cell epitopes within a solvent exposed, immunodominant α-helix in ricin toxin's enzymatic subunit | |
| CN112105373A (zh) | 治疗b型肝炎病毒感染的方法 | |
| TW202320782A (zh) | 癌症治療組合 |